Sex-based differences in cardiac ischaemic injury and protection: Therapeutic implications

British Journal of Pharmacology

Volumn 171, Issue 3, 2014, Pages 541-554

  Ostadal, B ^a   Ostadal, P ^b  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b NA HOMOLCE HOSPITAL   (Czech Republic)

Author keywords

acute coronary syndrome; cardioprotection; heart; ischaemia reperfusion injury; oestrogen; sex differences; therapeutic implications

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANDROGEN RECEPTOR; ANDROSTENEDIONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CLOPIDOGREL; CYTOKINE; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; ESTROGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; G PROTEIN COUPLED RECEPTOR; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; PRASTERONE; PRASUGREL; PROPRANOLOL; SEX HORMONE; TESTOSTERONE; TICLOPIDINE; TIROFIBAN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CLINICAL RESEARCH; DRUG MECHANISM; ESTROGEN THERAPY; FEMALE; HEART ATRIUM REMODELING; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MALE; MOUSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RABBIT; RAT; REPERFUSION INJURY; REVIEW; RISK REDUCTION; SEX DIFFERENCE;

ACUTE CORONARY SYNDROME; CARDIOPROTECTION; HEART; ISCHAEMIA/REPERFUSION INJURY; OESTROGEN; SEX DIFFERENCES; THERAPEUTIC IMPLICATIONS;

ACUTE CORONARY SYNDROME; ANDROGENS; ANIMALS; CARDIOVASCULAR AGENTS; DISEASE SUSCEPTIBILITY; ESTROGENS; EVIDENCE-BASED MEDICINE; FEMALE; HEART; HUMANS; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; SEX CHARACTERISTICS;

EID: 84892414805     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12270     Document Type: Review

References (148)

1. Alexander SPH, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
2. Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A, (2009). Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Am Heart J 157: 141-148.
3. Alfredsson J, Stenestrand U, Wallentin L, Swahn E, (2007). Gender differences in management and outcome in non-ST-elevation acute coronary syndrome. Heart 93: 1357-1362.
4. Arias-Loza PA, Jazbutyte V, Pelzer T, (2008). Genetic and pharmacologic strategies to determine the function of estrogen receptor alpha and estrogen receptor beta in cardiovascular system. Gend Med 5: S34-S45.
5. Bae S, Zhang L, (2005). Gender differences in cardioprotection against ischemia/reperfusion injury in adult rat hearts: focus on Akt and protein kinase C signaling. J Pharmacol Exp Ther 315: 1125-1135.
6. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-1860.
7. Barker DJ, (2000). In utero programming of cardiovascular disease. Theriogenology 53: 555-574.
8. Barker DJ, Osmond C, Golding J, Wadsworth M, (1989). Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 289: 564-567.
9. Barker WH, Mullooly JP, Getchell W, (2006). Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 113: 799-805.
10. Bassuk SS, Manson JE, (2010). Gender-specific aspects of selected coronary heart disease risk factors: a summary of the epidemiologic evidence. In:, Legato MJ, (ed.). Principles of Gender-Specific Medicine. Elsevier Inc: Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo, pp. 162-174.
11. Bazet H, (1920). An analysis of the time-relations of electrocardiograms. Heart 7: 353-370.
12. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, et al. (2006). Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295: 1420-1427.
13. Bell JR, Porrello ER, Huggins CE, Harrap SB, Delbridge LM, (2008). The intrinsic resistance of female hearts to an ischemic insult is abrogated in primary cardiac hypertrophy. Am J Physiol Heart Circ Physiol 294: H1541-H1522.
14. 2+, sex and sex steroids. Clin Exp Pharmacol Physiol 38: 717-723.
15. Besik J, Szarszoi O, Kunes J, Netuka I, Maly J, Kolar F, et al. (2007). Tolerance to acute ischemia in adult male and female spontaneously hypertensive rats. Physiol Res 56: 267-274.
16. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van der Werf F, et al. (2002). Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359: 189-198.
17. Bolli R, Becker L, Gross G, Mentzer R, Jr, Balsha WD, Lathrop DA, (2004). Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95: 125-134.
18. Booth EA, Lucchesi BR, (2008). Estrogen-mediated protection in myocardial ischemia-reperfusion injury. Cardiovasc Toxicol 8: 101-113.
19. Bopassa JC, Eghbali M, Toro L, Stefani E, (2010). A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 298: H16-H23.
20. Bouma W, Noma M, Kanemoto S, Matsubara M, Leshnower BG, Hinmon R, et al. (2010). Sex-related resistance to myocardial ischemia-reperfusion injury is associated with high constitutive ARC expression. Am J Physiol Heart Circ Physiol 298: H1510-H1517.
21. Camper-Kirby D, Welch S, Walker A, Shiraishi I, Setchell KDR, Schaefer E, et al. (2001). Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res 88: 1020-1027.
22. 5- enkephalin-induced cardioprotection: role of PI3K/Akt. Am J Physiol Heart Circ Physiol 294: H302-H310.
23. Capasso JM, Remily RM, Smith RH, Sonnenblick EH, (1983). Sex differences in myocardial contractility in the rat. Basic Res Cardiol 78: 156-171.
24. Capodanno D, Angiolillo DJ, (2010). Impact of race and gender on antithrombotic therapy. Thromb Haemost 104: 471-484.
25. Cavasin MA, Tao ZY, Yu AL, Yang XP, (2006). Testosterone enhances early cardiac remodeling after myocardial infarction causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol 290: H2043-H2050.
26. Chen Q, Yager JD, Russo J, (2005). Regulation of mitochondrial respiratory chain structure and function by estrogens/estrogen receptors and potential physiological/pathophysiological implications. Biochim Biophys Acta 1746: 1-17.
27. Chu SH, Sutherland K, Beck J, Kowalski J, Goldspink P, Schwertz D, (2005). Sex differences in expression of calcium-handling proteins and beta-adrenergic receptors in rat heart ventricle. Life Sci 76: 2735-2749.
28. Clark C, Smith W, Lochner A, Du Toit EF, (2011). The effects of gender and obesity on myocardial tolerance to ischemia. Physiol Res 60: 291-301.
29. Cohen M, Antman EM, Gurfinkel EP, Radley D, (2001). Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups. J Thromb Thrombolysis 12: 199-206.
30. 2 production and oxidative damage. Cardiovasc Res 74: 456-465.
31. Crisostomo PR, Wang M, Wairiuko GM, Terrell AM, Meldrum DR, (2006). Postconditioning in females depends on injury severity. J Surg Res 134: 342-347.
32. 2+ exchanger increases susceptibility to ischemia/reperfusion injury in male, but not female transgenic mice. Circ Res 83: 1215-1223.
33. Cross HR, Seenbergen C, Lefkowitz RJ, Koch WJ, Murphy E, (1999). Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-14 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ Res 85: 1077-1084.
34. 2+ loading and adrenergic stimulation reveal male/female differences in susceptibility to ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 283: H481-H489.
35. Cross HR, Murphy E, Koch WJ, Steenbergen C, (2002b). Male and female mice overexpressing the beta(2)-adrenergic receptor exhibit differences in ischemia/reperfusion injury: role of nitric oxide. Cardiovasc Res 53: 662-671.
36. Cross HR, Kranias EG, Murphy E, Steenbergen C, (2003). Ablation of PLB exacerbates ischemic injury to extent in female than male mice: protective role of NO. Am J Physiol Heart Circ Physiol 284: H683-H690.
37. 2+ channel modulation. Eur J Pharmacol 586: 288-292.
38. Czubryt MP, Espira L, Lamoureux L, Abrenica B, (2006). The role of sex in cardiac function and disease. Can J Physiol Pharmacol 84: 93-109.
39. De Simone G, Devreux RB, Daniels SR, Meyer RA, (1995). Gender differences in left ventricular growth. Hypertension 26: 979-983.
40. Deschamps AM, Murphy E, (2009). Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 297: H1806-H1813.
41. Deschamps AM, Murphy E, Sun J, (2010). Estrogen receptor activation and cardioprotection in ischemia reperfusion injury. Trends Cardiovasc Med 20: 73-78.
42. Di Lisa F, (2006). A female way to protect the heart. Say NO to calcium. Circ Res 98: 298-300.
43. Dow J, Kloner RA, (2007). Postconditioning does not reduce myocardial infarct size in an in vivo regional ischemia rodent model. J Cardiovasc Pharmacol Ther 12: 153-163.
44. Duvall WL, (2003). Cardiovascular disease in women. Mt Sinai J Med 70: 293-305.
45. Enriquez JR, Pratap P, Zbilut J, Calvin JE, Volgman AS, (2008). Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. Gend Med 5: 53-61.
46. Farrell SR, Ross JL, Howlet SE, (2010). Sex differences in mechanisms of cardiac excitation-contraction coupling in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 299: H36-H45.
47. Fischer M, Baessler A, Schunkert H, (2002). Renin-angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 53: 672-677.
48. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. (2000). Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355: 1575-1581.
49. FRISC Study Group (1996). Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 347: 561-568.
50. Gabel SA, Walker VR, London RE, Steenbergen C, Korach KS, Murphy E, (2005). Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol 38: 289-297.
51. Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A, et al. (1996). Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 93: 870-878.
52. Grohé C, Kahlert S, Löbbert K, Vetter H, (1998). Expression of oestrogen receptor α and β in rat heart: role of local oestrogen synthesis. J Endocrinol 156: R1-R7.
53. Guerra S, Leri A, Wang X, Finato N, Di Lorento C, Beltrami CA, et al. (1999). Myocyte death in the failing human heart is gender dependent. Circ Res 85: 856-866.
54. Hausenloy DJ, Yellon DM, (2009). Cardioprotection. Oxford University Press Inc: New York, 126.
55. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. (2000). Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343: 522-529.
56. Heusch G, (2004). Postconditioning: old wine in a new bottle? J Am Coll Cardiol 44: 1111-1112.
57. Hulley S, Grandy D, Bush T, Furberk C, Herrington D, Riggs B, et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605-612.
58. Humphreys RA, Kane KA, Parratt JR, (1999). The influence of maturation and gender on the anti-arrhythmic effect of ischaemic preconditioning in rats. Basic Res Cardiol 94: 1-8.
59. Jeanes HI, Tabor C, Black D, Ederveen A, Gray GA, (2008). Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER)α agonist and unaffected by an ERβ antagonist. J Endocrinol 197: 493-501.
60. Jochmann N, Stang K, Garbe E, Baumann G, Stangl V, (2005). Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26: 1585-1595.
61. ATP channel blockade in rat. Am J Physiol Heart Circ Physiol 290: H2644-H2647.
62. Knowlton AA, Lee AR, (2012). Estrogen and the cardiovascular system. Pharmacol Ther 135: 54-70.
63. Koh KK, Yoon BK, (2006). Controversies regarding hormone therapy: insights from inflammation and hemostasis. Cardiovasc Res 70: 22-30.
64. Kolar F, Ostadal B, (2013). Sex differences in cardiovascular function. Acta Physiol (Oxf) 207: 584-587.
65. Kolar F, Novak F, Neckar J, Novakova O, Ostadal B, Musters RJP, (2009). Role of protein kinases in chronic intermittent hypoxia-induced cardioprotection. In:, Xi L, Serebrovskaya TV, (eds). Intermittent Hypoxia. Science Publishers, Inc: New York, pp. 213-230.
66. Lagranha CJ, Deschamps A, Aponte A, Steenbergen C, Murphy E, (2010). Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res 106: 1681-1691.
67. Leblanc N, Chartier D, Gosselin H, Rouleau JL, (1998). Age and gender differences in excitation-contraction coupling of the rat ventricle. J Physiol 511: 533-548.
68. Lee DS, Steinbaugh GE, Quarrie R, Yang F, Talukder MAH, Zweier JL, et al. (2010a). Ischemic postconditioning does not provide cardioprotection from long-term ischemic injury in isolated male or female rat hearts. J Surg Res 164: 175-181.
69. Lee LC, Poh KK, Tang TP, Tan YL, Tee HW, Tan HC, (2010b). The impact of gender on the outcomes of invasive versus conservative management of patients with non-ST-segment elevation myocardial infarction. Ann Acad Med Singapore 39: 168-172.
70. Lee TM, Su SF, Tsai CC, Lee YT, Tsai CH, (2000). Cardioprotective effects of 17 beta-estradiol produced by activation of mitochondrial ATP-sensitive K(+) channels in canine hearts. J Mol Cell Cardiol 32: 1147-1158.
71. Legato MJ, Colman C, (1991). The Female Heart: The Truth about Women and Coronary Artery Disease. Prentice Hall: New York, 252.
72. Legato MJ, Leghe JK, (2010). Gender and the heart: sex-specific differences in the normal myocardial anatomy and physiology. In:, Legato MJ, (ed.). Principles of Gender-Specific Medicine. Elsevier Inc: Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo, pp. 151-161.
73. Leinwand LA, (2003). Sex is a potent modifier of the cardiovascular system. J Clin Invest 112: 302-304.
74. Li G, Xiao Y, Estrella JL, Ducsay CA, Gilbert RD, Zhang L, (2003). Effect of fetal hypoxia on heart susceptibility to ischemia and reperfusion injury in the adult heart. J Soc Gynecol Investig 10: 265-274.
75. Li G, Bae S, Zhang L, (2004). Effect of prenatal hypoxia on heat stress-mediated cardioprotection in adult rat heart. Am J Physiol Heart Circ Physiol 286: H1712-H1719.
76. Li Y, Kloner RA, (1995). Is there a gender difference in infarct size and arrhythmias following experimental coronary occlusion and reperfusion? J Thromb Thrombolysis 2: 221-225.
77. Lujan HL, DiCarlo SE, (2008). Sex differences to myocardial ischemia and beta-adrenergic receptor blockade in conscious rats. Am J Physiol Heart Circ Physiol 294: H1523-H1529.
78. 2+/calmodulin-dependent protein kinase II. Br J Pharmacol 157: 705-715.
79. Maas AH, Appelman YE, (2010). Gender differences in coronary heart disease. Neth Heart J 18: 598-603.
80. McHugh NA, Cook SM, Schairer JL, Bidgoli MM, Merrill GF, (1995). Ischemia and reperfusion-induced ventricular arrhythmias in dogs: effects of estrogen. Am J Physiol Heart Circ Physiol 268: H2569-H2573.
81. Madsen JK, Chevalier B, Darius H, Rutsch W, Wojcik J, Schneider S, et al. (2008). Ischaemic events and bleeding in patients undergoing percutaneous coronary intervention with concomitant bivalirudin treatment. EuroIntervention 3: 610-616.
82. Magness RR, Parker CR, Jr, Rosenfeld CR, (1993). Systemic and uterine responses to chronic infusion of estradiol-17β. Am J Physiol Endocrinol Metab 265: E690-E698.
83. Mendelsohn ME, (2005). Molecular and cellular basis of cardiovascular gender differences. Science 308: 1583-1587.
84. Mendelsohn ME, Karas RH, (1999). The protective effects of estrogen on the cardiovascular system. N Engl J Med 340: 1801-1811.
85. Mikkola TS, Clarkson TB, (2002). Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 53: 605-619.
86. Morey AK, Pedram A, Razandi M, Prins BA, Hu RM, Biesiada E, et al. (1997). Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 138: 3330-3339.
87. Morkuniene R, Arandarcikaite O, Ivanoviene L, Borutaite V, (2010). Estradiol-induced protection against ischemia-induced heart mitochondrial damage and caspase activation is mediated by protein kinase G. Biochim Biophys Acta 1797: 1012-1017.
88. Motovska Z, Widimsky P, Aschermann M, (2008). The impact of gender on outcomes of patients with ST elevation myocardial infarction transported for percutaneous coronary intervention: analysis of the PRAGUE-1 and 2 studies. Heart 94: e5.
89. Murphy E, (2011). Estrogen signaling and cardiovascular disease. Circ Res 109: 687-696.
90. Murphy E, Steenbergen C, (2007). Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc Res 75: 478-486.
91. Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, et al. (2007). Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 100: 1047-1051.
92. Netuka I, Szarszoi O, Maly J, Besik J, Neckar J, Ostadalova I, et al. (2006). Effect of perinatal hypoxia on cardiac tolerance to acute ischaemia in adult male and female rats. Clin Exp Pharmacol Physiol 33: 714-719.
93. Nguyen HL, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Gurfinkel EP, et al. (2010). Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry. Coron Artery Dis 21: 336-344.
94. Nicolau JC, Auxiliadora Ferraz M, Nogueira PR, Coimbra Garzon A, Serrano CV, Jr, Ramires JA, (2004). The role of gender in the long-term prognosis of patients with myocardial infarction submitted to fibrinolytic treatment. Ann Epidemiol 14: 17-23.
95. Nikolic I, Liu D, Bell J, Collins J, Steenbergen C, Murphy E, (2007). Treatment with an estrogen receptor beta selective agonist is cardioprotective. J Mol Cell Cardiol 42: 769-780.
96. Olivetti G, Giordano G, Corradi D, Melissati M, Lagrasta C, Gambert SR, et al. (1995). Gender differences and aging: effects on the human heart. J Am Coll Cardiol 26: 1068-1079.
97. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, et al. (1992). Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 13: 28-32.
98. Ostadal B, (2009). The past, the present and the future of experimental research on myocardial ischemia and protection. Pharmacol Rep 61: 3-12.
99. Ostadal B, Prochazka J, Pelouch V, Urbanova D, Widimsky J, (1984). Comparison of cardiopulmonary responses of male and female rats to intermittent high altitude hypoxia. Physiol Bohemoslov 33: 129-138.
100. Ostadal B, Ostadalova I, Dhalla NS, (1999). Development of cardiac sensitivity to oxygen deficiency: comparative and ontogenetic aspects. Phys Rev 79: 635-659.
101. Ostadal B, Netuka I, Maly J, Besik J, Ostadalova I, (2009). Gender differences in cardiac ischemic injury and protection-experimental aspects. Exp Biol Med (Maywood) 234: 1011-1019.
102. Ostadal B, Ostadalova I, Kolar F, Netuka I, Szarszoi O, (2012). Impact of perinatal chronic hypoxia on cardiac tolerance to acute ischemia. In:, Dhalla NS, Nagano M, Ostadal B, (eds). Molecular Defects in Cardiovascular Disease. Springer: New York, Dordrecht, Heidelberg, London, pp. 55-67.
103. Ostadal P, Ostadal B, (2012). Women and the management of acute coronary syndrome. Can J Physiol Pharmacol 90: 1151-1159.
104. Ostadalova I, Ostadal B, Kolar F, Parratt JR, Wilson S, (1998). Tolerance to ischaemia and ischaemic preconditioning in neonatal rat heart. J Mol Cell Cardiol 30: 857-865.
105. Patterson AJ, Chen M, Xue Xiao D, Zhang L, (2010). Chronic prenatal hypoxia induces epigenetic programming of PKCε gene expression in rat hearts. Circ Res 107: 365-373.
106. Pavon N, Martinez-Abundis E, Hernandez L, Gallardo-Perez JC, Alvarez-Delgado C, Cerbon M, et al. (2012). Sexual hormones: effects on cardiac and mitochondrial activity after ischemia-reperfusion in adult rats. Gender difference. J Steroid Biochem Mol Biol 132: 135-146.
107. Penna C, Tullio F, Merlino A, Moro F, Raimondo S, Rastaldo R, et al. (2009). Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender. Basic Res Cardiol 104: 390-402.
108. Petre RE, Quaile MP, Rossman EI, Ratcliffe SJ, Bailey BA, Houser SR, et al. (2007). Sex-based differences in myocardial contractile reserve. Am J Physiol Regul Integr Comp Physiol 292: R810-R818.
109. Piro M, Bona RD, Abbate A, Biasucci LM, Crea F, (2010). Sex-related differences in myocardial remodeling. J Am Coll Cardiol 55: 1057-1065.
110. Przyklenk K, Ovize M, Bauer B, Kloner RA, (1995). Gender does not influence acute myocardial infarction in adult dogs. Am Heart J 129: 1108-1113.
111. Radovanovic D, Erne P, Urban P, Bertel O, Rickli H, Gaspoz JM, (2007). Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20,290 patients from the AMIS Plus Registry. Heart 93: 1369-1375.
112. Regitz-Zagrosek V, (2006). Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5: 425-439.
113. Regitz-Zagrosek V, Oertelt-Prigione S, Seeland U, Hetzer R, (2010). Sex and gender differences in myocardial hypertrophy and heart failure. Circ J 74: 1265-1273.
114. Reynolds HR, Farkouh ME, Lincoff AM, Hsu A, Swahn E, Sadowski ZP, et al. (2007). Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med 167: 2054-2060.
115. Rohlicek CV, Matsuoka T, Saiki C, (2002). Cardiovascular response to acute hypoxemia in adult rats hypoxemic neonatally. Cardiovasc Res 53: 263-270.
116. Ross JL, Howlet SE, (2012). Age and ovariectomy abolish beneficial effects of female sex on rat ventricular myocytes exposed to simulated ischemia and reperfusion. PLoS ONE 7: e38425 (1-11).
117. Rossano GM, Sarrel PM, Poole-Wilson PA, Collins P, (1993). Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 342: 133-136.
118. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg CH, Hutchinson F, et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized control trial. JAMA 288: 321-333.
119. Rossouw JE, Prentice RL, Manon JE, Manson JE, Wu L, Barad D, et al. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465-1477.
120. Rozenberg S, Vandromme J, Antoine C, (2013). Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol 9: 216-227.
121. Sack MN, Rader DJ, Cannon RO, (1994). Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 343: 269-270.
122. Schaible TF, Scheuer J, (1984). Comparison of heart function in male and female rats. Basic Res Cardiol 79: 402-412.
123. Smith PJ, Ornatsky O, Stewart DJ, Picard P, Dawood F, Wen WH, et al. (2000). Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation 102: 2983-2989.
124. Song X, Li G, Vaage J, Valen G, (2003). Effects of sex, gonadectomy, and oestrogen substitution on ischaemic preconditioning and ischaemia-reperfusion injury in mice. Acta Physiol Scand 177: 459-466.
125. Steg PG, Greenlaw N, Tardif JC, Tendera M, Ford I, Kaab S, et al. (2012). Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J 33: 2831-2840.
126. Steingart RM, Packer M, Hamm P, Coglianese ME, Gersh B, Geltman EM, et al. (1991). Sex differences in the management of coronary artery disease. N Engl J Med 325: 226-230.
127. Stirone C, Duckles SP, Krause DN, Procaccio V, (2005). Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 68: 959-965.
128. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, et al. (2007). Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369: 907-919.
129. Sun J, Picht E, Ginsburg KS, Bers DM, Steenbergen C, Murphy E, (2006). Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel {alpha} 1 subunit and reduced ischemia-reperfusion injury. Circ Res 98: 403-411.
130. Talukder MAH, Yang F, Shimokawa H, Zweier JL, (2010). eNOS is required for acute in vivo ischemic preconditioning of the heart: effects of ischemic duration and sex. Am J Physiol Heart Circ Physiol 299: H437-H445.
131. Tobin JN, Wassertheil-Smoller S, Wexler JP, Steingart RM, Budner N, Lense L, et al. (1987). Sex bias in considering coronary-bypass surgery. Ann Intern Med 107: 19-25.
132. Tong H, Imahashi K, Steenbergen C, Murphy E, (2002). Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol -3-kinase-dependent pathway is cardioprotective. Circ Res 90: 377-379.
133. Toss H, Wallentin L, Siegbahn A, (1999). Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J 137: 72-78.
134. Tsang S, Wu S, Liu J, Wong TM, (2008). Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation. Br J Pharmacol 153: 693-709.
135. Turcato S, Turnbull L, Wang GY, Honbo N, Simpson PC, Karliner JS, et al. (2006). Ischemic preconditioning depends on age and gender. Basic Res Cardiol 101: 235-243.
136. Vaccarino V, Badimon L, Corti R, De Wit C, Dorobantu M, Hall A, et al. (2011). Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Cardiovasc Res 90: 9-17.
137. Van Eickels M, Grohé C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA, (2001). 17β-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104: 1419-1423.
138. Vikman S, Airaksinen KE, Tierala I, Peuhkurinen K, Majamaa-Voltti K, Niemela M, et al. (2007). Gender-related differences in the management of non-ST-elevation acute coronary syndrome patients. Scand Cardiovasc J 41: 287-293.
139. Wang CH, Chiari PC, Weihrauch D, Kroliowski JG, Warltier DC, Kersten JR, et al. (2006a). Gender-specificity of delayed preconditioning by isoflurane in rabbits: potential role of endothelial nitric oxide synthase. Anesth Analg 103: 274-280.
140. Wang CM, Crisostomo P, Wairiuko GM, Meldrum DR, (2006b). Estrogen receptor-alpha mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol 290: H2204-H2209.
141. Wang M, Wang Y, Weil B, Abarbanell A, Herrmann J, Tan J, et al. (2009). Estrogen receptor beta mediates increasec activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. Am J Physiol Regul Integr Comp Physiol 296: R972-R978.
142. Wenger NK, (2008). Preventing cardiovascular disease in women: an update. Clin Cardiol 31: 109-113.
143. White HD, Barbash GI, Modan M, Simes J, Diaz R, Hampton JR, et al. (1993). After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. Circulation 88: 2097-2103.
144. Xu Y, Arenas IA, Armstrong SJ, Plahta WC, Xu H, Davidge ST, (2006). Estrogen improves cardiac recovery after ischemia/reperfusion by decreasing tumor necrosis factor-α. Cardiovasc Res 69: 836-844.
145. Xue Q, Zhang L, (2009). Prenatal hypoxia causes a sex-dependent increase in heart susceptibility to ischaemia and reperfusion injury in adult male offspring: role of protein kinase Cε. J Pharmacol Exp Ther 330: 624-632.
146. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. (2006). Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354: 1464-1476.
147. Zhai P, Eurell TE, Cooke PS, Lubahn DB, Gross DR, (2000). Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice. Am J Physiol Heart Circ Physiol 278: H1640-H1647.
148. Zheng Z, Yang M, Zhang F, Yu J, Wang J, Ma L, et al. (2011). Gender-related difference of sevoflurane postconditioning in isolated rat hearts: focus on phosphatidylinositol-3-kinase/Akt signaling. J Surg Res 170: e3-e9.